gms | German Medical Science

25th Annual Meeting of the German Drug Utilisation Research Group (GAA)

Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie

22.11. - 23.11.2018, Bonn/Bad Godesberg


Meeting Abstract (18gaa01)

„QT-Life“: Prevention of adverse drug effects, in particular torsade de pointes-events, by pharmacy-based basic data collection

Bodmer T, Augustin M, Froese P, Volmer T
[Full Text]
Meeting Abstract (18gaa02)

Use of proton pump inhibitors at the University hospital Jena

Farker K, Hildwein D, Kummer S, Hartmann M
[Full Text]
Meeting Abstract (18gaa03)

Epidemiology, outcomes and treatment patterns among patients with coronary artery disease and/or peripheral artery disease treated in routine clinical practice in Germany

Beier D, Galetzka W, Hickstein L, Meinhardt M, Häckl D, Schmedt N
[Full Text]
Meeting Abstract (18gaa04)

Pharmaceutical advice by phone enhances use of infliximab biosimilars

van Eijk SC, Arndt LK, Neitemeier S
[Full Text]
Meeting Abstract (18gaa05)

Data quality of pharmaceutical claims data – How to measure, assess and improve?

Heck N, Jacke C
[Full Text]
Meeting Abstract (18gaa06)

Agranulocytosis attributed to metamizole: an analysis of spontaneous reports in EudraVigilance 1985–2017

Hoffmann F, Bantel C, Jobski K
[Full Text]
Meeting Abstract (18gaa07)

Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,248 patients treated in Germany

Wilke T, Gottschalk F, Groth A, Brandes A, Ratsch B, Fuchs A, Deiters B, Bokemeyer B
[Full Text]
Meeting Abstract (18gaa09)

Contaminated valsartan: how were patients affected

Selke GW, Schüssel K, Langner I, Eichler U
[Full Text]
Meeting Abstract (18gaa10)

Patients with polypharmacy: How many physicians and pharmacies are involved?

Lappe V, Ihle P, Schubert I, Grandt D
[Full Text]
Meeting Abstract (18gaa11)

Benefit of a clinical pharmacist on a German surgical intensive care unit – A controlled interventional study

Kessemeier N, Meyn D, Höckel M, Reitze J, Culmsee C, Tryba M
[Full Text]
Meeting Abstract (18gaa12)

Two years’ experience of using morbidity related groups (MRG) for economic evaluation of drug prescriptions in outpatient care in Schleswig-Holstein

Schuster R, Heidbreder M, Emcke T
[Full Text]
Meeting Abstract (18gaa13)

A hospital standard on “Good Practice in Prescribing Medicines” – a quality parameter and set of minimum requirements for computerised physician order entry (CPOE) systems

Vogt W, Buchelt M, Hanel A, Eberlein-Gonska M, Knoth H
[Full Text]
Meeting Abstract (18gaa14)

Medication Analysis for Hospital Patients with Renal Insufficiency: from project development to service establishment

Kastner B, Speckner W, Albrecht J
[Full Text]
Meeting Abstract (18gaa15)

Development of a deprescribing guideline for the COFRAIL study: Family conferences and shared prioritisation to improve patient safety in the frail elderly. A cluster randomised intervention trial in primary care

Mann NK, Schmiedl S, Altiner A, Icks A, Meyer G, Mortsiefer A, Wiese B, Wilm S, Thürmann PA
[Full Text]
Meeting Abstract (18gaa16)

Hospital pharmacy aspects of discharge management in Baden-Wuerttemberg hospitals – survey results 2017 and future perspectives

von Ameln-Mayerhofer A, Weissbarth A, Ausschuss Krankenhauspharmazie
[Full Text]
Meeting Abstract (18gaa17)

A survey among health care professionals regarding electronic health record systems

Neininger MP, Bellstedt LM, Bertsche T
[Full Text]
Meeting Abstract (18gaa18)

Using failure mode and effects analysis to increase patients’ safety in chemotherapy

Weber L, Schulze I, Jaehde U
[Full Text]
Meeting Abstract (18gaa19)

Influence of metabolic profiles on drug safety in routine care in Germany – the EMPAR project

Huebner T, Steffens M, Fracowiak J, Gomm W, Roethlein C, Garling M, Langner D, Linder R, Haenisch B, Stingl J
[Full Text]
Meeting Abstract (18gaa20)

Antiepileptic drug use and dementia risk – analyses of Finnish Health Register and German Health Insurance data

Taipale H, Gomm W, Broich K, Maier W, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Haenisch B
[Full Text]
Meeting Abstract (18gaa21)

The most frequently reported adverse drug reactions and suspected drugs – descriptive analysis of spontaneous reports contained in the adverse drug reaction database of the Federal Institute for Drugs and Medical Devices in Germany (1978–2016)

Dubrall D, Schmid M, Alešik E, Paeschke N, Stingl J, Sachs B
[Full Text]